Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
44
GMAB Quote, Financials, Valuation and Earnings
Last price:
$31.47
Seasonality move
:
5.43%
Day range:
$30.35 - $31.50
52-week range:
$17.24 - $33.96
Dividend yield:
0%
P/E ratio:
13.08x
P/S ratio:
5.39x
P/B ratio:
3.29x
Volume:
1.9M
Avg. volume:
1.5M
1-year change:
47.58%
Market cap:
$18.9B
Revenue:
$3.1B
EPS (TTM):
$2.35
Analysts' Opinion
-
Consensus RatingGenmab A/S has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.81, Genmab A/S has an estimated upside of 22.77% from its current price of $30.80.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $26.00 representing 15.58% downside risk from its current price of $30.80.
Fair Value
-
According to the consensus of 8 analysts, Genmab A/S has 22.77% upside to fair value with a price target of $37.81 per share.
GMAB vs. S&P 500
-
Over the past 5 trading days, Genmab A/S has underperformed the S&P 500 by -7.34% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Genmab A/S does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Genmab A/S has grown year-over-year revenues for 7 quarters straight. In the most recent quarter Genmab A/S reported revenues of $1B.
Earnings Growth
-
Genmab A/S has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Genmab A/S reported earnings per share of $0.64.
Enterprise value:
15.7B
EV / Invested capital:
--
Price / LTM sales:
5.39x
EV / EBIT:
11.85x
EV / Revenue:
4.37x
PEG ratio (5yr expected):
0.10x
EV / Free cash flow:
12.90x
Price / Operating cash flow:
15.93x
Enterprise value / EBITDA:
11.28x
Gross Profit (TTM):
$3.4B
Return On Assets:
22.93%
Net Income Margin (TTM):
41.34%
Return On Equity:
28.3%
Return On Invested Capital:
27.54%
Operating Margin:
44.91%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $2.4B | $2.9B | $3.6B | $815.7M | $1B | |
| Gross Profit | $1.3B | $2.8B | $3.4B | $775.5M | $959.7M | |
| Operating Income | $886M | $931.5M | $1.3B | $312M | $457M | |
| EBITDA | -- | -- | $1.4B | $328.4M | $474.9M | |
| Diluted EPS | $0.93 | $1.04 | $2.35 | $0.29 | $0.64 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.4B | $3.8B | $4.7B | $3.5B | $4.5B | |
| Total Assets | $3.7B | $4B | $5B | $5.9B | $7B | |
| Current Liabilities | $285.2M | $393.7M | $412M | $686.4M | $741M | |
| Total Liabilities | $420.8M | $530.8M | $585.8M | $1.2B | $1.3B | |
| Total Equity | $3.3B | $3.5B | $4.4B | $4.8B | $5.8B | |
| Total Debt | $68.1M | $82.9M | $112.6M | $147.8M | $142M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $879.4M | $964.8M | $1.3B | $296.6M | $536.8M | |
| Cash From Investing | -$134.2M | -$1.5B | -$64.8M | $28.1M | -$54.2M | |
| Cash From Financing | -$64.3M | -$571.8M | -$443.5M | -$41.7M | -$19.5M | |
| Free Cash Flow | $819.5M | $940.8M | $1.2B | $289.6M | $535M | |
GMAB
Sector
Market Cap
$18.9B
$28.1M
Price % of 52-Week High
90.7%
50%
Dividend Yield
0%
0%
Shareholder Yield
2.21%
-1.54%
1-Year Price Total Return
47.58%
-17.67%
Beta (5-Year)
0.899
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$32.63
200-day SMA
Buy
Level
$25.12
Bollinger Bands (100)
Buy
Level
26.46 - 32.4
Chaikin Money Flow
Buy
Level
75.7M
20-day SMA
Sell
Level
$32.02
Relative Strength Index (RSI14)
Sell
Level
42.97
ADX Line
Sell
Level
23.13
Williams %R
Buy
Level
-87.5346
50-day SMA
Sell
Level
$30.81
MACD (12, 26)
Buy
Level
0.34
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
67.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.6149)
Buy
CA Score
(Annual)
Level (2.1145)
Sell
Beneish M-Score
(Annual)
Level (12.9034)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-5.3004)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
Stock Forecast FAQ
In the current month, GMAB has received 6 Buy ratings 2 Hold ratings, and 0 Sell ratings. The GMAB average analyst price target in the past 3 months is $37.81.
-
Where Will Genmab A/S Stock Be In 1 Year?
According to analysts, the consensus estimate is that Genmab A/S share price will rise to $37.81 per share over the next 12 months.
-
What Do Analysts Say About Genmab A/S?
Analysts are divided on their view about Genmab A/S share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Genmab A/S is a Sell and believe this share price will drop from its current level to $26.00.
-
What Is Genmab A/S's Price Target?
The price target for Genmab A/S over the next 1-year time period is forecast to be $37.81 according to 8 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is GMAB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Genmab A/S is a Buy. 6 of 8 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GMAB?
You can purchase shares of Genmab A/S via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Genmab A/S shares.
-
What Is The Genmab A/S Share Price Today?
Genmab A/S was last trading at $31.47 per share. This represents the most recent stock quote for Genmab A/S. Yesterday, Genmab A/S closed at $30.80 per share.
-
How To Buy Genmab A/S Stock Online?
In order to purchase Genmab A/S stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GMAB Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GMAB
Sector
P/E ratio
13.08x
23.88x
PEG ratio
0.10x
-0.01x
P/B ratio
3.29x
1.82x
Price / LTM sales
5.39x
1.59x
Growth Metrics
GMAB
Sector
Revenue growth
24.73%
4.73%
Earnings growth
120.47%
11.11%
Revenue (5-year growth)
31.16%
6.46%
Earnings forecast
$0.42
-$0.18
Profitability
GMAB
Sector
Profitability FY 2024
$2.9B
$3.6M
Return on invested capital
27.54%
-31.77%
Return on assets
22.93%
-28.18%
Return on equity
28.3%
-37.47%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
5
Estimated Next Earnings Date
Feb
5
Balance Sheet
GMAB
Sector
Total cash
$3.4B
$26.3M
Short term investments
$1.6B
$26M
Total assets
$6.4B
$76.9M
Long term debt
$142M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 2
Corcept Therapeutics, Inc. [CORT] is up 5.11% over the past day.
Buy
75
AXSM alert for Jan 2
Axsome Therapeutics, Inc. [AXSM] is down 3.83% over the past day.
Sell
50
NUTX alert for Jan 2
Nutex Health, Inc. [NUTX] is down 9.63% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
